ADMA Biologics Reports Full Year 2018 Financial Results

Ramsey, New Jersey, UNITED STATES

RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases, today announced its financial results for the year ended December 31, 2018, and provided an update on its operations and upcoming milestones.

“During 2018, we achieved several key objectives, most notably the improvement of our Boca Raton, FL manufacturing facility’s FDA compliance status to Voluntary Action Indicated (“VAI”).  This improved VAI classification has afforded us the opportunity to submit regulatory applications to the U.S. Food and Drug Administration (the “FDA”) for potential approval of new drug product candidates,” stated Adam Grossman, President and Chief Executive Officer of ADMA.

“As part of our compliance enhancement upgrades to our Boca Raton, FL facility, we optimized the intravenous immunoglobulin (“IVIG”) manufacturing process for BIVIGAM®. We continue to work with the FDA to finalize our BIVIGAM Prior Approval Supplement (“PAS”) for drug substance, with the goal of reintroducing BIVIGAM® to the market this year. We are also working closely with the FDA on the pending application for RI-002’s initial approval, and the FDA action date is scheduled for April 2, 2019,” continued Mr. Grossman.

“Other notable accomplishments include: retiring approximately 8.6 million shares of our non-voting common stock from Biotest Pharmaceuticals Corporation, receiving FDA approval of our plasma collection center in Kennesaw, GA, obtaining FDA approval for the BIVIGAM® drug product PAS and completing a debt refinancing of up to $72.5 million with Perceptive Advisors.”

Mr. Grossman concluded, “We look forward to continuing to work with the FDA during 2019 as we seek FDA approval for the pending applications for both RI-002 and BIVIGAM®.  FDA approval for RI-002 and BIVIGAM®, if received, along with Nabi-HB®, our presently commercially available hyperimmune globulin, would give us three commercial immune globulin products  and would make ADMA one of the few globally recognized plasma manufacturers offering a portfolio of novel immune globulin products.” 

Recent Achievements and Upcoming Milestones

  • Improved compliance status for the Boca Raton, FL facility to VAI, enabling ADMA to submit regulatory applications for FDA review and potential approval

  • Obtained FDA approval for our Kennesaw, GA plasma collection center

  • Completed a debt refinancing of up to $72.5 million with Perceptive Advisors

  • Ongoing work with the FDA to obtain approval of the BIVIGAM® drug substance PAS in order to relaunch the product

  • Prescription Drug User Fee Act action date of April 2, 2019 for RI-002

  • Potential commercial sales of BIVIGAM® and RI-002

  • Continue to produce, release and market commercial product for Nabi-HB® in the U.S.

  • Expand promotional activities for Nabi-HB

Financial Results for the Year Ended December 31, 2018

ADMA reported total revenues of $17.0 million for the year ended December 31, 2018, as compared to $22.8 million for the year ended December 31, 2017, representing a decrease of $5.8 million.  The decrease in revenues is primarily due to $7.0 million of non-recurring revenue generated in 2017 that was related to an amendment to our contract manufacturing agreement and a decrease in the sale of normal source plasma of $1.6 million in 2018 due to increased competition from other plasma donation centers which have opened in close proximity to the plasma collection centers we transferred to Biotest on January 1, 2019, partially offset by an increase in Nabi-HB revenues of $2.8 million. 

The consolidated net loss for the year ended December 31, 2018 was $65.7 million, or $(1.45) per basic and diluted share, as compared to a consolidated net loss of $43.8 million, or $(1.91) per basic and diluted share for the year ended December 31, 2017. The increase in net loss of $22.0 million was primarily attributable to an increase in cost of product revenue from the manufacture of conformance lots production of RI-002 and BIVIGAM®, which can be used for commercial sales upon FDA approval, higher operational expenses reflecting a full year of operations at the Boca Raton, FL facility for 2018, as compared to just seven months of operating activity at the Boca Raton, FL facility in 2017, as well as the initiation of marketing and commercial activities and the decrease in revenues.  Included in the net loss for the year ended December 31, 2018 were non-cash expenses of $6.8 million for stock-based compensation, depreciation and amortization, and non-cash interest expense.  

At December 31, 2018, ADMA had cash and cash equivalents of $22.8 million, as compared to $43.1 million at December 31, 2017. ADMA’s net working capital was $34.9 million as of December 31, 2018, as compared to $52.9 million as of December 31, 2017.

About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-based biologics for the treatment of immune deficiencies and the prevention of and treatment of certain infectious diseases.  The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886 and 9,969,793 related to certain aspects of its lead product candidate, RI-002.  For more information, please visit

BIVIGAM® is an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency. This includes, but is not limited to, agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These primary immunodeficiencies (“PI”) are a group of genetic disorders. Initially thought to be very rare, it is now believed that as many as 250,000 people in the U.S. have some form of PI. BIVIGAM® contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses, and help to protect Primary Immune Deficiency Disease (“PIDD”) patients against serious infections. BIVIGAM® is a purified, sterile, ready-to-use preparation of concentrated polyclonal Immunoglobulin (“IgG”) antibodies. Antibodies are proteins in the human immune system that work to defend against infections and disease. FDA’s initial approval for BIVIGAM® was received by Biotest Pharmaceuticals Corporation on December 19, 2012, and production of BIVIGAM® was halted by Biotest in December 2016.  ADMA obtained ownership and all rights, title and interest in BIVIGAM® on June 6, 2017 as part of the Biotest Therapy Business Unit asset acquisition and resumed the production of BIVIGAM® during the fourth quarter of 2017. 

About RI-002
ADMA's lead portfolio product candidate, RI-002, which has demonstrated positive Phase III pivotal clinical trial data, is a specialty plasma-derived, polyclonal, intravenous immune globulin (“IVIG”) derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus (“CMV”), measles, tetanus, etc.) as well as plasma from donors tested to have high levels of neutralizing antibodies to respiratory syncytial virus (“RSV”). ADMA is pursuing an indication for the use of this specialty polyclonal IVIG product for treatment of patients diagnosed with PIDD. Polyclonal antibodies are the primary active component of IVIG products. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. Data review which has been published in peer reviewed journals indicates that the polyclonal antibodies present in RI-002 support its ability to prevent infections in immune-compromised patients.  This data and other information about RI-002 or ADMA Biologics products can be found on the Company website at:  RI-002 is manufactured with novel technology protected by U.S. Patents: 9,107,906, 9,714,283, 9,815,886 and 9,969,793, the latter of which affords ADMA patent exclusivity for the use of an immune globulin as a prevention and/or treatment for any type of respiratory infection. 

About Primary Immune Deficiency Disease (PIDD)
PIDD is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.  According to the World Health Organization, there are approximately 350 different genetic mutations encompassing PIDD. Some disorders present at birth or in early childhood, the disorders can affect anyone regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of the system. PIDD patients are vulnerable to infections and more likely to suffer complications from these infections as compared to individuals with a normal functioning immune system. The infections may occur in any part of the body. As patients suffering from PIDD lack a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products. Without this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PIDD has an estimated prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we“, “our” or the “Company”).  Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," “project,” "intend," “forecast,” "target,” ”anticipate,” “plan,” “planning,” “expect,” “believe,” “will," “is likely,” “will likely,” “should,” “could,” "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to develop, manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products, the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current products and product candidates, and the labeling or nature of any such approvals, the success of our work with our third party vendors and the U.S. Food and Drug Administration (the “FDA”) in furtherance of and progress towards an approval of our Biologics License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately or in a timely manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities, the timeframe within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential of our specialty plasma-based biologics to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or other indications, our ability to realize increased prices for plasma growth in the plasma collection industry and our expectations for future capital requirements and availability of future capital. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

Brian Lenz
Executive Vice President and Chief Financial Officer | 201-478-5552 |

Jeremy Feffer
Managing Director, LifeSci Advisors, LLC | 212-915-2568 |

Years Ended December 31, 2018 and 2017
  Years Ended December 31,
   2018   2017 
Product revenue $  16,842,456  $  15,617,726 
License revenue    142,834     142,834 
Other revenue    -      7,000,000 
Total Revenues    16,985,290     22,760,560 
Cost of product revenue (exclusive of amortization expense shown below)    42,194,635     29,164,321 
Research and development    3,926,120     5,570,029 
Plasma center operating expenses    7,805,619     6,503,750 
Asset impairment charge    -      845,389 
Amortization of intangible assets    844,938     1,234,674 
Selling, general and administrative    22,502,922     18,752,393 
Total operating expenses    77,274,234     62,070,556 
LOSS FROM OPERATIONS    (60,288,944)    (39,309,996)
Interest income    195,403     57,228 
Interest expense    (5,522,783)    (3,285,847)
Loss on extinguishment of debt    -      (1,210,216)
Other expense    (127,121)    (10,144)
Other expense, net    (5,454,501)    (4,448,979)
NET LOSS $  (65,743,445) $  (43,758,975)
Basic and Diluted  45,188,899   22,896,042 


 December 31, December 31,
  2018   2017 
Current assets:   
Cash and cash equivalents$  22,754,852  $  43,107,574 
Accounts receivable, net   1,392,441     3,880,154 
Inventories   18,616,169     12,628,181 
Prepaid expenses and other current assets   1,766,163     1,225,654 
Restricted cash   -      1,500,000 
Total current assets   44,529,625     62,341,563 
Property and equipment, net   30,115,730     30,466,858 
Intangible assets, net   4,004,412     4,849,350 
Goodwill   3,529,509     3,529,509 
Assets to be transferred under purchase agreement   1,153,508     1,496,410 
Restricted cash   4,000,000     4,000,000 
Deposits and other assets   1,543,737     1,335,143 
TOTAL ASSETS$  88,876,521  $  108,018,833 
Current liabilities:   
Accounts payable$  5,900,394  $  5,920,873 
Accrued expenses and other current liabilities   3,551,835     3,376,476 
Current portion of deferred revenue   142,834     142,834 
Current portion of capital lease obligation   29,983     -  
Total current liabilities   9,625,046     9,440,183 
Notes payable, net of discount   26,440,830     25,368,458 
End of term liability, notes payable   2,760,000     2,760,000 
Deferred revenue, net of current portion   2,404,365     2,547,199 
Note payable - related party, net of discount   14,874,184     14,842,396 
Obligation to transfer assets under purchase agreement   12,621,844     12,621,844 
Capital lease obligation   119,080     -  
Other non-current liabilities   260,734     105,996 
TOTAL LIABILITIES   69,106,083     67,686,076 
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding   -      -  
Common Stock - voting, $0.0001 par value, 75,000,000 shares   
authorized, 46,353,068 and 36,725,499 shares issued and outstanding   4,635     3,673 
Common Stock - non-voting, $0.0001 par value, 8,591,160 shares   
authorized, 0 and 8,591,160 shares issued and outstanding   -      859 
Additional paid-in capital   236,203,041     191,022,018 
Accumulated deficit   (216,437,238)    (150,693,793)
TOTAL STOCKHOLDERS' EQUITY    19,770,438     40,332,757